BIOXYTRAN, INC. (BIXT)
Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence
Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence
📈 **POSITIVE** • Medium confidence analysis (76%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (87%) **Content type:** Clinical